Orthopedic Medical Devices & Rehabilitation Technology
Strategic Profile
After a major spin-off in April 2022 that separated its industrial ESAB business, the company completed its transformation into a pure-play medical technology company. In September 2023, Enovis announced a definitive agreement to acquire LimaCorporate for approximately €800 million, which strengthens its reconstructive orthopedics portfolio. The company operates through two segments: Prevention and Recovery (consumer-focused products) and Reconstructive (surgical solutions).
Cyborg Score Rationale
The company generated $2.25B in trailing twelve-month revenue, demonstrating solid market presence. However, the company reported negative EPS of -$20.75 for the twelve-month period, indicating significant profitability challenges. The market cap of approximately $1.46B suggests modest valuation relative to its revenue base.
Top Insights
Pure-play orthopedic focus achieved through strategic spin-off and divestments, with enhanced portfolio through LimaCorporate acquisition